CVR number 29603537
Industry 46.4610 Wholesale of pharmaceutical goods

Novozymes Biopharma DK A/S

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...
Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  4.4% 2.5% 4.2% 10.2% 18.6%  
Credit score (0-100)  49 62 47 23 7  
Credit rating  BBB BBB BBB BB B  
Credit limit (kDKK)  0.0 0.4 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales  0 0 0 0 0  
Gross profit  316,786 47,194 58,720 -399 912  
EBITDA  316,786 47,194 58,720 -399 912  
EBIT  316,786 47,194 58,720 -399 912  
Pre-tax profit (PTP)  317,554.9 52,622.4 65,011.6 265,728.1 19,112.5  
Net earnings  247,692.9 41,162.3 51,118.9 266,066.3 14,907.7  
Pre-tax profit without non-rec. items  317,555 52,622 65,012 265,728 19,112  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  356,192 97,354 108,473 321,539 71,447  
Interest-bearing liabilities  685 148 0.0 122 133  
Balance sheet total (assets)  542,398 167,512 123,196 322,996 75,920  
Net Debt  163 -281 -464 -379 -374  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales  0 0 0 0 0  
Net sales growth  -100.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  316,786 47,194 58,720 -399 912  
Gross profit growth  295.3% -85.1% 24.4% 0.0% 0.0%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  542,398 167,512 123,196 322,996 75,920  
Balance sheet change%  350.3% -69.1% -26.5% 162.2% -76.5%  
Added value  316,786.2 47,194.2 58,720.4 -399.2 911.8  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  
Net sales trend  -3.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 -1.0 1.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  96.2% 15.1% 47.8% 120.7% 9.7%  
ROI %  111.8% 17.4% 52.9% 125.2% 9.9%  
ROE %  106.6% 18.2% 49.7% 123.7% 7.6%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  65.7% 58.1% 88.0% 99.5% 94.1%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.1% -0.6% -0.8% 94.8% -41.1%  
Gearing %  0.2% 0.2% 0.0% 0.0% 0.2%  
Net interest  0 0 0 0 0  
Financing costs %  221.0% 248.3% 5,958.3% 5,667.1% 245.1%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  6.6 12.4 8.4 221.7 17.0  
Current Ratio  6.6 12.4 8.4 221.7 17.0  
Cash and cash equivalent  522.7 429.4 464.5 500.5 507.5  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  68.4 97.2 281.2 0.0 430.9  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  460,560.7 153,877.6 108,297.4 321,539.5 71,447.2  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0